So AMBS/Avant own right to NuroPro, another blood-based developmental diagnostic test for Parkinson's as well as Alzheimer's. This test has proven very effective in early studies, but, again, it's progression has been sluggish due to lack of money to advance it. Below is a short news article on the early studies of NuroPro done back in 2009. NuroPro in my opinion is also extremely valuable IP that AMBS/Avant hold but lack the money to move forward currently.

https://www.healthitoutcomes.com/doc/transgen...oduce-0001

note: AMBS bought NuroPro from Power3. Actually the new IP notice that came out a few weeks ago was additional IP protection for AMBS on NuroPro.